Enzymatica’s mouth spray to be launched in Turkey
4 April 2022
Non-regulatory press release
Enzymatica’s mouth spray to be launched in Turkey
Enzymatica’s mouth spray against the common cold will be launched in Turkey, following the approval as a medical device in the country. This opens a new market of more than 80 million consumers.
The Turkish cough and cold market has an estimated worth of approximately EUR 1.1 billion and has shown a steady growth during the last years. Now Enzymatica’s mouth spray against the common cold will be launched in Turkey, following the approval as a medical device by TITCK, the Turkish Medicines and Medical Devices Agency.
“Turkey is a large market with great future potential. We are happy that the product will be launched shortly, following a smooth and prompt approval process where safety and clinical performance data were reviewed”, said Claus Egstrand, CEO of Enzymatica.
The product will be marketed, sold, and distributed in Turkey by Sanofi Consumer Health Care under one of its own brands.
FOR MORE INFORMATION, PLEASE CONTACT:
Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com
Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 (0) 708 55 11 85 | Email: stefan.olsson@enzymatica.com
Enzymatica AB develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The
products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device
ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 4 continents. The
strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing
markets and expanding into new geographic markets through established partners. The company has its headquarters in
Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit: www.enzymatica.com.